Tacrolimus, a calcineurin inhibitor, has been demonstrated to protect against the inflammation-induced tissue and bone loss associated with periodontitis in experimental rats and oral diseases through a mechanism involving IL-1β, TNF-α, and IL-6 [29, 30]. This evidence concerns the gene IL6 and mouth disorder.